- Home
- NTIP vs ANTX Comparison
NTIP vs ANTX Comparison
Compare NTIP & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NTIP | ANTX |
|---|---|---|
| Founded | 1990 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.0M | 31.2M |
| IPO Year | 1998 | 2022 |
Fundamental Metrics
Financial Performance| Metric | NTIP | ANTX |
|---|---|---|
| Price | $1.31 | $1.12 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $2.00 |
| AVG Volume (30 Days) | 17.6K | ★ 58.5K |
| Earning Date | 11-06-2025 | 11-12-2025 |
| Dividend Yield | ★ 7.63% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $150,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.16 | $1.01 |
| 52 Week High | $1.90 | $1.55 |
Technical Indicators
Market Signals| Indicator | NTIP | ANTX |
|---|---|---|
| Relative Strength Index (RSI) | 39.56 | 50.17 |
| Support Level | $1.32 | $1.03 |
| Resistance Level | $1.42 | $1.15 |
| Average True Range (ATR) | 0.05 | 0.08 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 9.01 | 50.00 |
Price Performance
Historical ComparisonAbout NTIP Network-1 Technologies Inc.
Network-1 Technologies Inc is involved in the business of the development, licensing, and protection of intellectual property assets. The company's current plan includes continuing to pursue licensing opportunities for its intellectual property assets.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.